Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study.
Cavanagh
Jonathan
J
Paterson
Carolyn
C
McLean
John
J
Pimlott
Sally
S
McDonald
Moira
M
Patterson
James
J
Wyper
David
D
McInnes
Iain
I
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D006801:Humans; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D050486:Serotonin Plasma Membrane Transport Proteins; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab